Novavax (NVAX +1.9%) says it's begun enrollment for Phase 1 clinical trials of its A(H7N9)...


Novavax (NVAX +1.9%) says it's begun enrollment for Phase 1 clinical trials of its A(H7N9) vaccine candidate for the prevention of avian flu. Research on the drug has progressed rapidly, moving from viral gene sequencing, to vaccine candidacy, to multiple animal studies, and now, just three months after the gene sequence was obtained, into a clinical trial.

From other sites
Comments (1)
  • Scrying Biotech
    , contributor
    Comments (2479) | Send Message
     
    This is not simply a demonstration of the alacrity of Novavax' VLP technology. It's a strategy to move these vaccines on to the commercial market before any other producer does thereby realizing actual revenue.

     

    Brilliant!
    8 Jul 2013, 02:43 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs